




Treatment and Guidelines of Juvenile Idiopathic Arthritis

CP-377704
Апрель 2023

Материал предназначен для медицинских и фармацевтических работников. Материал разработан Янссен, подразделением фармацевтических товаров ООО «Джонсон & Джонсон».

Johnson & Johnson» LLC branch in RK
#42, Timiryazev Street, Building 23-a
Almaty, 050040, Republic of Kazakhstan
Website: www.janssen.com/kazakhstan

Treatment Options in JIA




*Therapies tested in high-quality paediatric studies; CAPS: cryopyrin-associated autoinflammatory syndromes; cDMARD: conventional disease-modifying drug; EMA, European Medicines Agency; E-oJIA, extended oligoarticular juvenile idiopathic arthritis; ERA: enthesitis-related arthritis; IL-1-RA, IL-1 receptor antagonist; JIA: juvenile idiopathic arthritis; oJIA: oligoarticular juvenile idiopathic arthritis; pJIA: polyarticular juvenile idiopathic arthritis; psA: psoriatic arthritis; sJIA: systemic juvenile idiopathic arthritis; TNFi: tumour necrosis factor inhibitor; yo: years old

Hinze et al. *Nat Rev Rheumatol* 2015;11:290-300.

Simponi® (golimumab) Summary of Product Characteristics (SmPC); dated 24JUN2016.


ACR Recommendations for the Treatment of JIA

Treatment recommendations for patients with a history of arthritis of ≥ 5 joints




*Leflunomide may be an appropriate treatment alternative; NSAID: non-steroidal anti-inflammatory drugs;
MTX: methotrexate; TNF: tumor necrosis factor

CARRA Recommendations for the Treatment of New-Onset Polyarticular JIA




*Any inhibitor of tumor necrosis factor, T cell costimulation, interleukin-6, or B cell; DMARD: Disease modified anti-rheumatic drug; MD: physician; CARRA: Childhood Arthritis and Rheumatology Research Alliance

CARRA Recommendations for the Treatment of New-Onset Polyarticular JIA (Cont'd)



*Methotrexate, sulfasalazine, or leflunomide; #any inhibitor of tumor necrosis factor, T cell costimulation, interleukin-6, or B cell
DMARD: Disease modified anti-rheumatic drug; MD: physician.

CARRA Recommendations for the Treatment of New-Onset Polyarticular JIA (Cont'd)



*Methotrexate, sulfasalazine, or leflunomide; #Any inhibitor of tumor necrosis factor, T cell costimulation, interleukin-6, or B cell
DMARD: Disease modified anti-rheumatic drug; MD: physician.

Adapted from Ringold et al. *Arthritis Care Res* 2014;66:1063-72.